Cost–Effectiveness of Combinatorial Pharmacogenomic Testing for Depression from the Canadian Public Payer Perspective
Open Access
- 17 April 2020
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 21 (8) , 521-531
Abstract
Aim: Evaluate cost–effectiveness of combinatorial pharmacogenomic (PGx) testing, versus treatment as usual (TAU), to guide treatment for patients with depression, from the Canadian public healthcar...Keywords
Funding Information
- Assurex Health
This publication has 16 references indexed in Scilit:
- Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatristsJournal of Psychiatric Research, 2018
- Describing the population health burden of depression: health-adjusted life expectancy by depression status in CanadaHealth Promotion and Chronic Disease Prevention in Canada, 2016
- Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluationCurrent Medical Research and Opinion, 2015
- A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013Psychiatric Services, 2014
- Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenetics and Genomics, 2013
- Using a pharmacogenomic algorithm to guide the treatment of depressionTranslational Psychiatry, 2012
- Interpreting the Results of Cost-Effectiveness StudiesJACC, 2008
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic reviewThe Lancet, 2003